

Annual report 2021: The Abacus Medicine Group overcame challenging markets affected by COVID-19 to record high revenue growth

Revenue rose 42% to EUR 941 million through growth in all three business areas of the Group

The Abacus Medicine Group faced challenging market conditions in 2021 as millions of treatments were postponed due to COVID-19. Today, the Group announces revenue growth of 42% to EUR 941 million. Organic growth was 19%, when adjusted for the effect of the Pluripharm business being included in the numbers with 12 months in 2021 against 5 months in 2020. EBITDA of EUR 16.6 million was a also new record for the company.

The EBITDA result for the Dutch pharmaceutical wholesaler Pluripharm improved to EUR 0.5 million in 2021. This is an important milestone in the turnaround of the Pluripharm business, as it marks the return to a positive result after consecutive years of negative EBITDA.

CEO Flemming Wagner says: “We posted growth in all of our three business areas: Abacus Medicine (Parallel Distribution), Pluripharm and Abacus Medicine Pharma Services. In markets with weaker demand because of COVID-19, this is highly satisfactory, even if profitability was below our long-term ambition.”

Profit before tax was EUR 2.1 million.

Key Figures (In EUR'000)	2020	2021
Revenue	663,501	940,740
Gross Profit	67,557	81,535
Operating profit before depreciations and amortisation (EBITDA)	12,483	16,562
Profit for the year	433	415
Revenue growth	57.4%	41.8%
Gross margin	10.2%	8.7%
EBITDA margin	1.9%	1.8%

This year, the Abacus Medicine Group publishes a separate [Sustainability Report](#) for the first time.

Update on Ukraine

Everyone in the Abacus Medicine Group is deeply opposed to the tragic outbreak of war in Ukraine. For our colleagues with Ukrainian and Russian backgrounds the situation is of



course particularly difficult. We will do everything we can to support our employees in these uncertain times.

From our warehouse in Hungary, Abacus Medicine has donated relevant medicine and medical devices to Ukraine in cooperation with the parallel importers' organisation Affordable Medicines Europe. In the Netherlands, Pluripharm is organizing donations of medicine and medical devices from both us and from our pharmacy customers.

The war in Ukraine has no direct impact on the Abacus Medicine Group. We did no business in either Ukraine or Russia in 2021.

Contact

Abacus Medicine

Flemming Wagner, CEO

Mobile: +45 20 40 80 21, fw@abacusmedicine.com

Kasper Lytthans, Head of Investor Relations and M&A

Mobile: +45 30 80 89 16, kasper.lytthans@abacusmedicine.com

Ole Lindhardt, Head of Communications

Mobile: +45 20 18 39 52, ole.lindhardt@abacusmedicine.com